Compounds > sorafenib
Page last updated: 2024-09-05

sorafenib and Gastrointestinal Stromal Tumors

sorafenib has been researched along with Gastrointestinal Stromal Tumors in 22 studies

Research

Studies (22)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's8 (36.36)29.6817
2010's14 (63.64)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Fu, Y; Liang, J; Lin, L; Wei, X; Xu, W1
Canbay, A; Franck, C; Franke, S; Haybaeck, J; Rosania, R; Venerito, M1
Brzozowska, M; Czech, M; Potemski, P; Połowinczak-Przybyłek, J; Śliwczyński, A; Szafraniec-Buryło, S; Wierzba, W1
Chow, PK; Chung, A; Huynh, H; Lam, IW; Lee, JW; Lew, GB; Ngo, VC; Ong, HS; Soo, KC1
Chang, SE; Choi, JH; Kang, YK; Koh, JK; Lee, JL; Lee, MW; Lee, WJ; Moon, KC1
Wang, ZY1
Bonvalot, S; Cioffi, A; Dômont, J; Le Cesne, A; Tardieu, M1
Cano Megías, M; Carrasco De La Fuente, M; González Albarrán, O; Menacho Román, M; Pérez López, G1
Blay, JY; Chaigneau, L; Curtit, E; Dobi, E; Kalbacher, E; Mansi, L; Nguyen, T; Pivot, X; Viel, E1
Adenis, A; Antonescu, CR; Blay, JY; Bompas, E; Bui, B; Casali, P; Cioffi, A; Coco, P; Coindre, JM; Debiec-Rychter, M; Duffaud, F; Isambert, N; Italiano, A; Keohan, ML; Le Cesne, A; Maki, RG; Rutkowski, P; Schöffski, P; Toulmonde, M1
Im, SA; Kang, BY; Kang, YK; Kwon, HC; Lee, SS; Park, SH; Park, SR; Ryoo, BY; Ryu, MH1
Bui, B; Coindre, JM; Italiano, A; Kind, M; Maki, RG; Roubaud, G1
George, S; Hornick, JL; Jagannathan, JP; Ramaiya, NH; Shinagare, AB1
Donsky, RS; Fletcher, JA; Griffith, DJ; Heinrich, MC; Liang, CW; Marino-Enriquez, A; McKinley, A; Patterson, J; Presnell, A; Taguchi, T1
Benekli, M; Buyukberber, S; Cetin, B; Guz, G; Inal, S; Memis, L; Ozturk, SC; Turan, N1
Bauer, S; Bitz, U; Blay, JY; Duffaud, F; Gelderblom, H; Joensuu, H; Montemurro, M; Pink, D; Rutkowski, P; Schütte, J; Trent, J1
Bihan, H; Cohen, R; Coindre, JM; Des Guetz, G; Le Jeune, S; Mourad, JJ1
Marx, J1
King, CR1
Blanke, C1
Agaram, NP; Antonescu, CR; Besmer, P; Clarkson, BD; D'Adamo, D; DeMatteo, RP; Guo, T; Hom, G; Maki, RG; Schwartz, GK; Singer, S; Veach, D; Wong, GC1
Bui, B; Italiano, A1

Reviews

5 review(s) available for sorafenib and Gastrointestinal Stromal Tumors

ArticleYear
The BRAF Status May Predict Response to Sorafenib in Gastrointestinal Stromal Tumors Resistant to Imatinib, Sunitinib, and Regorafenib: Case Series and Review of the Literature.
    Digestion, 2019, Volume: 99, Issue:2

    Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Drug Substitution; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridines; Sorafenib; Sunitinib; Treatment Outcome

2019
[Bemusement and strategy on the efficacy of clinical application of targeted anticancer drugs].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2009, Volume: 31, Issue:9

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Benzenesulfonates; Bevacizumab; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Deoxycytidine; Drug Delivery Systems; Gastrointestinal Stromal Tumors; Gemcitabine; Humans; Imatinib Mesylate; Indoles; Neoplasms; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sunitinib

2009
[Focus on GIST management].
    Bulletin du cancer, 2010, Volume: 97, Issue:6

    Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Thiazoles

2010
Multitargeted agents for therapeutically challenging tumor: an introduction for oncology nurses.
    ONS news, 2006, Volume: 21, Issue:8 Suppl

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Delivery Systems; Drug Monitoring; Gastrointestinal Stromal Tumors; Humans; Indoles; Kidney Neoplasms; Niacinamide; Nurse's Role; Nursing Assessment; Oncology Nursing; Patient Education as Topic; Phenylurea Compounds; Pyridines; Pyrroles; Signal Transduction; Sorafenib; Sunitinib

2006
[Gastrointestinal stromal tumors: molecular aspects and therapeutic implications].
    Bulletin du cancer, 2008, Volume: 95, Issue:1

    Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Disease Progression; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Neoplasm Proteins; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperazines; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sorafenib; Staurosporine; Sunitinib; Thiazoles

2008

Trials

1 trial(s) available for sorafenib and Gastrointestinal Stromal Tumors

ArticleYear
Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group.
    Investigational new drugs, 2012, Volume: 30, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Asian People; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Genotype; Humans; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Receptor, Platelet-Derived Growth Factor alpha; Sorafenib; Treatment Outcome

2012

Other Studies

16 other study(ies) available for sorafenib and Gastrointestinal Stromal Tumors

ArticleYear
Adverse reactions of sorafenib, sunitinib, and imatinib in treating digestive system tumors.
    Thoracic cancer, 2018, Volume: 9, Issue:5

    Topics: Adult; Aged; Carcinoma, Hepatocellular; Diarrhea; Drug-Related Side Effects and Adverse Reactions; Female; Gastrointestinal Stromal Tumors; Humans; Hypertension; Imatinib Mesylate; Liver Neoplasms; Male; Middle Aged; Sorafenib; Sunitinib

2018
Real-World Evidence of Patient Outcome Following Treatment of Advanced Gastrointestinal Stromal Tumor (GIST) with Imatinib, Sunitinib, and Sorafenib in Publicly Funded Health Care in Poland.
    Medical science monitor : international medical journal of experimental and clinical research, 2019, May-23, Volume: 25

    Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Poland; Protein Kinase Inhibitors; Public Health Practice; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome

2019
Sorafenib induces growth suppression in mouse models of gastrointestinal stromal tumor.
    Molecular cancer therapeutics, 2009, Volume: 8, Issue:1

    Topics: Animals; Antineoplastic Agents; Base Sequence; Benzenesulfonates; Body Weight; Disease Models, Animal; Disease Progression; Exons; Gastrointestinal Stromal Tumors; Humans; MAP Kinase Signaling System; Mice; Mice, SCID; Mutation; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-kit; Pyridines; Sorafenib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2009
Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
    The British journal of dermatology, 2009, Volume: 161, Issue:5

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Drug Eruptions; Female; Foot Dermatoses; Gastrointestinal Stromal Tumors; Hand Dermatoses; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Retrospective Studies; Skin Diseases; Sorafenib; Stomatitis; Sunitinib; Young Adult

2009
[Management of hypothyroidism secondary to tyrosine kinase inhibitors: description of treatment in three distinct clinical settings].
    Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion, 2011, Volume: 58, Issue:2

    Topics: Adult; Benzamides; Benzenesulfonates; Carcinoma, Renal Cell; Choristoma; Female; Gastrointestinal Stromal Tumors; Humans; Hypothyroidism; Imatinib Mesylate; Indoles; Kidney Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Piperazines; Pleural Diseases; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Thymus Gland; Thyroxine

2011
[KIT and KIT: from biology to clinical use].
    Bulletin du cancer, 2012, Feb-01, Volume: 99, Issue:2

    Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Thiazoles

2012
Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib.
    Annals of surgical oncology, 2012, Volume: 19, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Niacinamide; Phenylurea Compounds; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Retrospective Studies; Risk Factors; Serum Albumin; Sorafenib; Sunitinib; Survival Rate; Young Adult

2012
Clinical activity of sorafenib in patients with advanced gastrointestinal stromal tumor bearing PDGFRA exon 18 mutation: a case series.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:3

    Topics: Antineoplastic Agents; Benzenesulfonates; Exons; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Mutation; Niacinamide; Phenylurea Compounds; Pyridines; Receptor, Platelet-Derived Growth Factor alpha; Sorafenib

2012
Intracranial metastasis from pediatric GI stromal tumor.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Apr-01, Volume: 30, Issue:10

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Brain Neoplasms; Drug Administration Schedule; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Piperazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Stomach Neoplasms; Sunitinib; Treatment Outcome

2012
Sorafenib inhibits many kinase mutations associated with drug-resistant gastrointestinal stromal tumors.
    Molecular cancer therapeutics, 2012, Volume: 11, Issue:8

    Topics: Benzamides; Benzenesulfonates; Cell Line, Tumor; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Inhibitory Concentration 50; Mutation; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Sorafenib

2012
Sunitinib- and sorafenib-induced nephrotic syndrome in a patient with gastrointestinal stromal tumor.
    The Annals of pharmacotherapy, 2012, Volume: 46, Issue:10

    Topics: Angiogenesis Inhibitors; Benzenesulfonates; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Indoles; Middle Aged; Nephrotic Syndrome; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib

2012
Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis.
    European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chemotherapy, Adjuvant; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Salvage Therapy; Sorafenib; Sunitinib; Treatment Outcome; Young Adult

2013
Refractory hypoglycemia controlled by sorafenib in solitary fibrous tumor.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Mar-20, Volume: 31, Issue:9

    Topics: Adult; Gastrointestinal Stromal Tumors; Humans; Hypoglycemia; Male; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Solitary Fibrous Tumors; Sorafenib

2013
Cancer. Encouraging results for second-generation antiangiogenesis drugs.
    Science (New York, N.Y.), 2005, May-27, Volume: 308, Issue:5726

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Clinical Trials as Topic; Gastrointestinal Stromal Tumors; Humans; Kidney Neoplasms; Neoplasms; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Sorafenib; United States; United States Food and Drug Administration; Vascular Endothelial Growth Factor A

2005
Current and future management of GIST.
    Clinical advances in hematology & oncology : H&O, 2006, Volume: 4, Issue:8

    Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Benzoquinones; Disease Progression; Dose-Response Relationship, Drug; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Lactams, Macrocyclic; Niacinamide; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome

2006
Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Aug-15, Volume: 13, Issue:16

    Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Benzenesulfonates; Cell Proliferation; Dasatinib; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mice; Mutation; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Sorafenib; Thiazoles

2007